Loriot, Yohann http://orcid.org/0000-0002-8338-1739
Kamal, Maud http://orcid.org/0000-0003-1466-0950
Syx, Laurene http://orcid.org/0009-0005-5749-0738
Nicolle, Remy http://orcid.org/0000-0001-8084-1173
Dupain, Celia
Mensourri, Naoual
Duquesne, Igor
Lavaud, Pernelle
Nicotra, Claudio
Ngocamus, Maud
Lacroix, Ludovic http://orcid.org/0000-0003-2535-1010
Tselikas, Lambros http://orcid.org/0000-0002-8878-4916
Crehange, Gilles
Friboulet, Luc http://orcid.org/0000-0002-1129-4978
Castel-Ajgal, Zahra
Neuzillet, Yann http://orcid.org/0000-0003-4345-3598
Borcoman, Edith
Beuzeboc, Philippe
Marret, Grégoire
Gutman, Tom
Wong, Jennifer
Radvanyi, Francois http://orcid.org/0000-0002-5696-6424
Dureau, Sylvain
Scoazec, Jean-Yves http://orcid.org/0000-0003-1604-6823
Servant, Nicolas http://orcid.org/0000-0003-1678-7410
Allory, Yves http://orcid.org/0000-0002-5526-077X
Besse, Benjamin http://orcid.org/0000-0001-5090-8189
Andre, Fabrice http://orcid.org/0000-0001-5795-8357
Le tourneau, Christophe http://orcid.org/0000-0001-9772-4686
Massard, Christophe
Bieche, Ivan
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-EQPX-03, ANR-10-INBS-09-08)
Article History
Received: 6 March 2024
Accepted: 20 September 2024
First Online: 4 October 2024
Competing interests
: C.L.T.: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology, Seattle Genetics. M.K.: Roche, AstraZeneca. Pernelle Lavaud: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Astra Zeneca, Sanofi, Astellas; Support for attending meetings and/or travail from Daichi, Ipsen, Astellas, Sanofi, Jannssen, Pfizer; Advisory board from Daichi. L.L.: Hospitalities, Travel, advice board, research grant last 5 years with: Abbott; Adept Field Solutions; Amgen; AstraZeneca; Beckman Coulter; Bayer Boeringer; BMS; Icomed; Illumina, Genomic Health; Guardant health; Lilly; Medimmune; Myriad; Novartis; Pfizer; QualWorld1; Roche; Siemens Healthineer; Taiho Oncology, Thermofisher Sc; VelaDx. E.R.: Travel, advice board, research grant: AstraZeneca, Roche, BMS, GSK, and Clovis. L.F.: Research funding from Debiopharm, Incyte, Relay Therapeutics and Nuvalent and Non financial support from Illumina Inc and Guardant Health. F.F.: no disclosures. Benjamin Besse: grants from 4D Pharma, AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, Celgene, Cergentis, Chugai Pharmaceutical, Da Voltera, Daiichi Sankyo, Eli Lilly, Ellipse Pharma, Eisai, F-Star, Genmab, Genzyme Corporation, GSK, Hedera Dx, Inivata, Ipsen, Janssen, MSD, Onxeo, OSE Immunotherapeutics, Pfizer, Pharmamar, Roche/Genentech, Sanofi, Socar Research, Taiho Oncology, Takeda, Tolero Pharmaceuticals, and Turning Point Therapeutics during the conduct of the study. C.M.: Consultant/Advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. Principal/sub-Investigator of Clinical Trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, Xencor. F.A.: grants from Roche, Lilly, Novartis, Pfizer, Daiichi Sankyo, and AstraZeneca outside the submitted work. Y.L.: personal fees, and non-financial support from Sanofi, Janssen, Astellas, Seattle Genetics, Gilead, AstraZeneca, BMS, MSD, Pfizer, Merck KGaA, Pfizer, and Tahio; grants, grants from Celsius, Sanofi, Roche, MSD. The remaining authors declare no competing interests.